BR112012008951A2 - tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd - Google Patents
tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpdInfo
- Publication number
- BR112012008951A2 BR112012008951A2 BR112012008951A BR112012008951A BR112012008951A2 BR 112012008951 A2 BR112012008951 A2 BR 112012008951A2 BR 112012008951 A BR112012008951 A BR 112012008951A BR 112012008951 A BR112012008951 A BR 112012008951A BR 112012008951 A2 BR112012008951 A2 BR 112012008951A2
- Authority
- BR
- Brazil
- Prior art keywords
- prodrugs
- dpd
- combinations
- treatment
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25144909P | 2009-10-14 | 2009-10-14 | |
| PCT/US2010/052734 WO2011047195A1 (en) | 2009-10-14 | 2010-10-14 | Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012008951A2 true BR112012008951A2 (pt) | 2019-09-24 |
Family
ID=43466528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012008951A BR112012008951A2 (pt) | 2009-10-14 | 2010-10-14 | tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8658618B2 (https=) |
| EP (1) | EP2488182B1 (https=) |
| JP (2) | JP2013508293A (https=) |
| KR (1) | KR20120127709A (https=) |
| CN (1) | CN102811721A (https=) |
| AU (1) | AU2010306698B2 (https=) |
| BR (1) | BR112012008951A2 (https=) |
| CA (1) | CA2777546C (https=) |
| CO (1) | CO6541596A2 (https=) |
| EA (1) | EA201270551A1 (https=) |
| ES (1) | ES2644237T3 (https=) |
| IL (1) | IL219179A0 (https=) |
| MX (1) | MX2012004383A (https=) |
| WO (1) | WO2011047195A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089004A1 (en) * | 2012-12-04 | 2014-06-12 | Adherex Technologies, Inc. | Methods for treating 5-fluorouracil prodrug non-responsive cancer patients |
| CN106692173A (zh) * | 2015-11-18 | 2017-05-24 | 北京诺普德医药科技有限公司 | 一种抗肿瘤复方组合物及其应用 |
| WO2024123736A1 (en) * | 2022-12-06 | 2024-06-13 | Elion Oncology, Inc. | Combined use of eniluracil and capecitabine for treating cancer |
| WO2025015267A1 (en) * | 2023-07-13 | 2025-01-16 | Processa Pharmaceuticals, Inc. | Methods of personalizing cancer treatment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5687599A (en) | 1979-12-19 | 1981-07-16 | Yamasa Shoyu Co Ltd | E 55 22halogenovinyl arabinofuranosyluracil and its preparation |
| GB8629892D0 (en) | 1986-12-15 | 1987-01-28 | Wellcome Found | Antiviral compounds |
| US5157114A (en) | 1988-08-19 | 1992-10-20 | Burroughs Wellcome Co. | 2',3'-dideoxy-3'-fluoro-5-ethyngluridine |
| WO1992001452A1 (en) | 1990-07-19 | 1992-02-06 | The Wellcome Foundation Limited | Enzyme inactivators |
| GB9020930D0 (en) * | 1990-09-26 | 1990-11-07 | Wellcome Found | Pharmaceutical combinations |
| US5476855A (en) | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| NZ330360A (en) | 1997-06-02 | 1999-03-29 | Hoffmann La Roche | 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| JP2008521930A (ja) * | 2004-12-03 | 2008-06-26 | アドヘレックス テクノロジーズ， インコーポレイテッド | ５−ｆｕおよび５−ｆｕプロドラッグと併用してｄｐｄ阻害物質を投与するための方法 |
-
2010
- 2010-10-14 JP JP2012534373A patent/JP2013508293A/ja active Pending
- 2010-10-14 KR KR1020127012289A patent/KR20120127709A/ko not_active Withdrawn
- 2010-10-14 ES ES10768670.1T patent/ES2644237T3/es active Active
- 2010-10-14 CN CN2010800562916A patent/CN102811721A/zh active Pending
- 2010-10-14 AU AU2010306698A patent/AU2010306698B2/en active Active
- 2010-10-14 MX MX2012004383A patent/MX2012004383A/es not_active Application Discontinuation
- 2010-10-14 US US12/904,974 patent/US8658618B2/en active Active
- 2010-10-14 EP EP10768670.1A patent/EP2488182B1/en active Active
- 2010-10-14 EA EA201270551A patent/EA201270551A1/ru unknown
- 2010-10-14 BR BR112012008951A patent/BR112012008951A2/pt not_active IP Right Cessation
- 2010-10-14 CA CA2777546A patent/CA2777546C/en active Active
- 2010-10-14 WO PCT/US2010/052734 patent/WO2011047195A1/en not_active Ceased
-
2012
- 2012-04-15 IL IL219179A patent/IL219179A0/en unknown
- 2012-05-14 CO CO12078833A patent/CO6541596A2/es not_active Application Discontinuation
-
2015
- 2015-09-29 JP JP2015190757A patent/JP2016014051A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010306698A1 (en) | 2012-05-17 |
| EP2488182A1 (en) | 2012-08-22 |
| AU2010306698B2 (en) | 2016-05-26 |
| CA2777546A1 (en) | 2011-04-21 |
| WO2011047195A1 (en) | 2011-04-21 |
| ES2644237T3 (es) | 2017-11-28 |
| EA201270551A1 (ru) | 2012-12-28 |
| MX2012004383A (es) | 2012-08-23 |
| CN102811721A (zh) | 2012-12-05 |
| JP2013508293A (ja) | 2013-03-07 |
| CO6541596A2 (es) | 2012-10-16 |
| JP2016014051A (ja) | 2016-01-28 |
| IL219179A0 (en) | 2012-06-28 |
| CA2777546C (en) | 2019-11-05 |
| US8658618B2 (en) | 2014-02-25 |
| EP2488182B1 (en) | 2017-07-19 |
| KR20120127709A (ko) | 2012-11-23 |
| US20110130359A1 (en) | 2011-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500203A1 (en) | Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors | |
| ECSP099376A (es) | Inhibidores de la actividad de la akt | |
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| GEP20166455B (en) | Methods of administering pirfenidone therapy | |
| PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
| BR112015012536A2 (pt) | tratamento de câncer com inibidores heterocíclicos da glutaminase | |
| CY1117440T1 (el) | Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido | |
| MX2009012197A (es) | Metodos para tratamiento de ulceras en la piel. | |
| WO2008147482A3 (en) | Methods and compositions for improving immune responses | |
| EP4512480A3 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| MX2012000817A (es) | Tratamiento para desordenes del higado con inhibidores pi3k. | |
| MX366774B (es) | Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1. | |
| MX365007B (es) | Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes. | |
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| EP2558102A4 (en) | SYNERGISTIC INTERACTION OF AT LEAST ONE COMPONENT OF VITAMIN E AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS | |
| BR112016004118A2 (pt) | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar | |
| BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
| MX347927B (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| MX2019013862A (es) | Terapia de combinacion. | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| BR112012008951A2 (pt) | tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |